CSL announced today [12 February 2021] that the final stages of the manufacturing of the AstraZeneca Covid-19 vaccine for Australia are planned to commence early next week at its Seqirus facility in Parkville, Victoria.
Two million doses of the vaccine are expected to be released at the end of March, subject to approval by the Therapeutic Goods Administration (TGA).
Reportedly, once the initial doses have been released, one million doses of the AztraZeneca vaccine, which is currently being considered by the TGA for use in Australia, will be released per week thereafter.
“Reaching this milestone would not have happened without around the clock work from our skilled team across both CSL Behring and Seqirus, with ongoing support from AstraZeneca,” says CSL’s Chief Scientific Officer Dr Andrew Nash.
“While the work isn’t over, we are incredibly proud to be on the cusp of delivering a locally made vaccine for Australians.
“Some of the most critical work is still to come – in particular, extensive quality checks that will be behind every finished vaccine.
“We continued to be heartened by the extraordinary amount of scientific collaboration happening across the industry, academia and government, as we all work towards the delivery of effective vaccines and therapies to address this pandemic.”